India Flu Diagnostic and Treatment Market - Strategic Insights and Forecasts (2026-2031)

The Indian flu diagnostic and treatment market is projected to register a strong CAGR during the forecast period (2026-2031).

Key Highlights

Market Overview

The need for flu diagnostics and treatment is shaped by seasonal influenza activity, outbreaks, respiratory symptoms that overlap with other infections, and the need to identify cases requiring closer monitoring. NCDC maintains seasonal influenza reporting, technical guidance, laboratory procedures, and a network for influenza testing, while ICMR operates dedicated surveillance and reference capabilities.

Clinical purchasing differs by care setting. Hospitals and reference laboratories place greater weight on analytical performance, throughput, quality control, subtype identification, and integration with existing molecular workflows. Clinics and physician offices place more value on turnaround time, ease of use, sample handling, and the ability to make treatment decisions during the consultation. Cost remains relevant across settings, but the acceptable price differs with patient severity and the clinical value of rapid results.

The market also has an unusual relationship between diagnostics and treatment. India’s NCDC clinical protocol recommends oseltamivir for specified patient categories and states that treatment should not be delayed while waiting for confirmatory testing. This reduces the extent to which antiviral demand depends on a positive diagnostic result, particularly in patients with severe disease or higher clinical risk.

Commercial opportunity therefore extends beyond standalone flu tests. Suppliers can gain from molecular platforms, multiplex respiratory panels, rapid immunoassays, laboratory automation, and recurring consumables. The strongest opportunities are likely to arise where testing supports faster clinical decisions, surveillance, infection control, or differentiation of influenza from other respiratory pathogens.

Key Market Indicators

NCDC reported 2,400 H1N1 cases and 13 deaths through June 30, 2025, based on reports received from States and Union Territories. The surveillance system should not be interpreted as a complete measure of influenza incidence because reporting depends on the cases and deaths submitted to the Central Surveillance Unit.

The public laboratory network provides a more direct indicator of diagnostic infrastructure. IDSP reported 441 district public health laboratories approved for strengthening through March 2026, with 397 performing according to recommended testing activity. The programme also reported 163 sanctioned State Referral Laboratories across 27 States and Union Territories.

Market Drivers

Expansion of integrated respiratory surveillance. India is strengthening influenza surveillance alongside monitoring of other respiratory viruses. WHO guidance now supports integrated surveillance covering specimen collection, testing, sequencing, data sharing, and analysis. ICMR also maintains an ILI-SARI surveillance dashboard and influenza surveillance infrastructure. This approach increases the value of diagnostic systems that can identify influenza A and B while also distinguishing other respiratory pathogens. Suppliers offering multiplex molecular assays can therefore address both routine clinical testing and public-health surveillance needs.

Demand for rapid results at the point of care. Clinical decisions often depend on whether respiratory symptoms are caused by influenza or another pathogen. Rapid molecular and immunoassay platforms can shorten the interval between specimen collection and treatment decisions. Abbott’s ID NOW Influenza A & B 2, for example, is designed for molecular detection at the point of care, while QuidelOrtho markets SOFIA influenza assays in India. These platforms compete on turnaround time, workflow simplicity, storage conditions, and the ability to operate outside centralized laboratories.

Expansion of multiplex respiratory testing. Influenza symptoms overlap with SARS-CoV-2, RSV, adenovirus, and other respiratory infections. ICMR’s 2026 invitation for technology transfer of a multiplex RT-PCR test covering influenza A and B, RSV A/B, and SARS-CoV-2 indicates institutional interest in broader respiratory testing. Multiplex panels can increase the clinical value of each specimen because one workflow can address several differential diagnoses. This favors suppliers that combine influenza detection with broader respiratory menus rather than relying only on standalone assays.

Strengthening public laboratory capacity. IDSP is linking district laboratories with State Referral Laboratories and improving access to confirmatory testing. NCDC also coordinates influenza laboratory activities and supports a network of laboratories performing respiratory-virus testing. Additional laboratory capability creates demand for instruments, reagents, controls, extraction systems, and test kits. Suppliers that can provide training, quality assurance, maintenance, and reliable consumable supply may gain an advantage where laboratories are expanding capacity rather than simply replacing existing equipment.

Market Restraints and Challenges

Clinical treatment can precede laboratory confirmation. NCDC’s clinical protocol recommends that appropriate patients receive oseltamivir without waiting for confirmatory test results. This limits the direct linkage between treatment sales and diagnostic testing volumes. For manufacturers of diagnostic products, the commercial case must therefore rest on clinical differentiation, surveillance, infection control, antibiotic stewardship, outbreak investigation, or treatment refinement rather than assuming that every antiviral prescription generates a diagnostic test.

Uneven testing capacity remains a structural constraint. India has expanded public laboratory infrastructure, but the distribution and capability of testing facilities vary across states and care settings. Molecular testing also requires trained personnel, validated workflows, quality controls, and dependable reagent supply. Smaller facilities may prefer rapid antigen or immunoassay formats because they require less laboratory infrastructure. Suppliers must therefore balance analytical performance against equipment cost, staff capability, maintenance needs, and sample logistics.

Diagnostic qualification and regulatory requirements can slow adoption. ICMR and CDSCO have formalized performance evaluation requirements for molecular in-vitro diagnostic devices covering influenza, SARS-CoV-2, and RSV. The 2025 protocol addresses analytical performance, cross-reactivity, lot-to-lot variation, internal controls, and nucleic-acid amplification formats. These requirements protect test quality but increase validation work for suppliers entering or expanding within the Indian market, particularly for multiplex assays and products requiring local performance evidence.

Seasonality creates utilization risk. Influenza testing demand can vary sharply with transmission patterns and outbreaks. A laboratory that invests in dedicated capacity must maintain adequate utilization outside peak periods. Multiplex platforms reduce this risk because the same instrument can support testing for several respiratory pathogens. Suppliers with broader assay menus can therefore make a stronger economic case than companies selling equipment or consumables tied only to influenza testing.

Major Segment Analysis

Molecular Tests / NAATs

Molecular Tests / NAATs represent a strategically important segment because they provide the analytical depth required for confirmatory testing, surveillance, and differentiation of influenza types and subtypes. ICMR’s 2025 performance protocol specifically covers singleplex and multiplex nucleic-acid amplification assays, including real-time RT-PCR formats. NCDC and ICMR reference laboratories also use molecular methods for influenza surveillance and characterization.

Hospitals, reference laboratories, public-health laboratories, and higher-volume diagnostic centers are the principal buyers. Their purchasing criteria extend beyond test sensitivity and specificity to throughput, automation, quality controls, reagent stability, instrument utilization, and service support. Multiplex capability can improve platform economics by allowing influenza testing to share infrastructure with SARS-CoV-2, RSV, and other respiratory targets. The main constraint is the higher infrastructure and workflow burden compared with rapid antigen formats, particularly where sample volumes are low.

Competitive Landscape

The competitive structure combines multinational diagnostic companies, specialized respiratory-testing suppliers, molecular platform providers, and companies with broader infectious-disease portfolios. F. Hoffmann-La Roche Ltd., Abbott Laboratories, Thermo Fisher Scientific Inc., Becton, Dickinson and Company, bioMérieux SA, QIAGEN N.V., QuidelOrtho Corporation, Cepheid, and SD Biosensor compete through assay breadth, instrument placement, turnaround time, automation, service, and distribution. Meridian Bioscience operates under SD Biosensor ownership, making the company relationship relevant when assessing the supplied competitive set.

Roche and QIAGEN are expanding syndromic molecular capabilities, while BD is adding respiratory assays to the BD MAX platform. Abbott competes strongly in near-patient molecular testing, and QuidelOrtho maintains a rapid immunoassay presence. bioMérieux competes through broad respiratory panels, including BIOFIRE systems. The resulting competition is increasingly platform-led because recurring reagent sales, assay menus, workflow integration, and service contracts can matter as much as individual influenza tests.

Recent Developments

• April 2026: ICMR invited expressions of interest for technology transfer of a multiplex RT-PCR test covering influenza A and B, RSV A/B, and SARS-CoV-2. The initiative can support domestic access to broader respiratory testing and may encourage local manufacturing or technology partnerships.

• December 2025: BD expanded the BD MAX menu with IVDR-certified VIASURE respiratory assays covering influenza A and B alongside other respiratory viruses. Broader menus strengthen the economics of molecular platforms by allowing laboratories to use one system across several respiratory indications.

• September 2025: QIAGEN launched QIAstat-Dx Rise in the United States with higher-throughput syndromic testing and respiratory panels. The development reflects continued movement toward automated molecular systems that can serve higher-volume laboratories.

• August 2025: Roche received FDA clearance for cobas Respiratory 4-flex, a multiplex respiratory assay using TAGS technology to detect and differentiate SARS-CoV-2, influenza A, influenza B, and RSV. The product illustrates the shift toward customizable respiratory testing on established high-throughput laboratory platforms.

Regulatory and Policy Environment

India’s regulatory environment combines medical-device oversight with public-health testing requirements. ICMR and CDSCO published a 2025 performance evaluation protocol for molecular in-vitro diagnostic devices covering influenza, SARS-CoV-2, and RSV. The protocol specifies analytical performance characteristics such as sensitivity, specificity, cross-reactivity, lot-to-lot variation, and internal controls. These requirements influence product validation, evidence generation, and the time required to commercialize new assays.

Public-health policy also affects the market through surveillance and laboratory networks. NCDC maintains technical guidance covering sample collection, laboratory procedures, patient categorization, clinical management, and reporting. IDSP links public laboratories to referral facilities for timely diagnostic support during suspected outbreaks. WHO’s integrated respiratory surveillance guidance further supports combining influenza surveillance with monitoring of other respiratory viruses.

Treatment policy has a direct commercial effect. NCDC recommends oseltamivir for specified patient categories and advises early treatment, preferably within 48 hours, without waiting for confirmatory testing in appropriate cases. This favors clinical decision support and rapid testing but also prevents diagnostic manufacturers from assuming that treatment demand will automatically translate into testing demand.

Outlook and Strategic Implications

The 2026-2031 market outlook will depend on how India balances centralized confirmation with faster testing closer to patients. Public laboratory strengthening should support the diagnostic base, while private hospitals and diagnostic chains can sustain demand for automated molecular platforms. Multiplex testing is likely to receive greater attention because it spreads instrument costs across several respiratory pathogens and aligns with integrated surveillance practices.

Supplier strategy will increasingly depend on platform economics rather than influenza alone. Companies that combine respiratory assays with automation, service support, quality controls, and flexible distribution can address a wider range of buyers. Local technology transfer, reagent availability, training, and regulatory support may also become important differentiators as government and private laboratories expand testing capability.

For buyers, the key decisions will center on total cost per reportable result, turnaround time, assay breadth, analytical performance, equipment utilization, and continuity of reagent supply. For suppliers and investors, the stronger commercial opportunities are likely to sit in scalable molecular workflows, multiplex respiratory testing, decentralized testing, and recurring consumables rather than in standalone influenza products. The market should therefore be assessed as part of India’s broader respiratory diagnostics and infectious-disease preparedness infrastructure, with influenza serving as a recurring clinical and surveillance application.

India Flu Diagnostic and Treatment Market Scope: